News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Genmab A/S Reduces Fair Value of Minnesota Manufacturing Facility to Zero, Moves Sale into 2013 and Updates 2012 Guidance
December 14, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Copenhagen, Denmark; December 13, 2012 – Genmab A/S (OMX: GEN) announces a change to the previous guidance from November 7, 2012 to reflect the reduction in value of the Minnesota manufacturing facility and a move of the sale into 2013.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Insights
Germany can produce biotech winners. Europe must back them better.
May 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Job Trends
Takeda cuts send layoffs soaring in May, rising year over year
May 19, 2026
·
4 min read
·
Angela Gabriel
Mergers & acquisitions
Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?
May 13, 2026
·
4 min read
·
Nick Paul Taylor
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
April 30, 2026
·
2 min read
·
Heather McKenzie